Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combi G-Vax
2024-512493-98-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of DC-VACCINE IRST-IRCCS and temozolomide in glioblastoma (GBM), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Progression-free survival at 3 months and Grade 3 or higher adverse events related to study treatment. Planned start Jul 2024; status: authorised.
02
Drugs
DC-VACCINE IRST-IRCCStemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-512493-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512493-98-00.